Elicio Therapeutics Reports Inducement Grants
Elicio Therapeutics (Nasdaq: ELTX), a clinical-stage biotechnology company focused on developing novel cancer immunotherapies, has announced the granting of inducement stock options to two new employees. The grants, approved by the Compensation Committee of Elicio's Board of Directors, were made under the company's 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
The details of the grants are as follows:
- Total options granted: 5,900
- Grant date: October 15, 2024
- Exercise price: $4.49 per share (closing price on grant date)
- Vesting schedule: 25% after one year, remainder vesting monthly over the following three years
These stock options serve as an inducement for the new employees joining Elicio Therapeutics and are subject to their continued employment with the company.
Elicio Therapeutics (Nasdaq: ELTX), un'azienda biotecnologica in fase clinica focalizzata sullo sviluppo di nuove immunoterapie per il cancro, ha annunciato il conferimento di opzioni azionarie di induzione a due nuovi dipendenti. I conferimenti, approvati dal Comitato per la Remunerazione del Consiglio di Amministrazione di Elicio, sono stati effettuati nell'ambito del Piano di Induzione e Incentivazione 2024 dell'azienda, in conformità con la Regola di quotazione 5635(c)(4) di Nasdaq.
I dettagli dei conferimenti sono i seguenti:
- Totale opzioni concesse: 5.900
- Data di concessione: 15 ottobre 2024
- Prezzo di esercizio: $4,49 per azione (prezzo di chiusura alla data di concessione)
- Programma di maturazione: 25% dopo un anno, il resto matura mensilmente nei successivi tre anni
Queste opzioni azionarie fungono da incentivo per i nuovi dipendenti che si uniscono a Elicio Therapeutics e sono soggette alla loro continuazione lavorativa con l'azienda.
Elicio Therapeutics (Nasdaq: ELTX), una compañía de biotecnología en fase clínica enfocada en el desarrollo de nuevas inmunoterapias contra el cáncer, ha anunciado la concesión de opciones sobre acciones de inducción a dos nuevos empleados. Las concesiones, aprobadas por el Comité de Compensación de la Junta Directiva de Elicio, se hicieron bajo el Plan de Premios de Incentivo de Inducción 2024 de la empresa, de acuerdo con la Regla de Cotización 5635(c)(4) de Nasdaq.
Los detalles de las concesiones son los siguientes:
- Total de opciones concedidas: 5,900
- Fecha de concesión: 15 de octubre de 2024
- Precio de ejercicio: $4.49 por acción (precio de cierre en la fecha de concesión)
- Programa de adquisición: 25% después de un año, el resto se adquiere mensualmente durante los siguientes tres años
Estas opciones sobre acciones sirven como incentivo para los nuevos empleados que se unen a Elicio Therapeutics y están sujetas a su empleo continuado con la empresa.
Elicio Therapeutics(Nasdaq: ELTX)는 새로운 암 면역요법 개발에 집중하는 임상 단계 생명공학 회사로, 두 명의 새로운 직원에게 유도 주식 옵션을 부여한다고 발표했습니다. 이 부여는 Elicio의 이사회 보상 위원회에서 승인되었으며, 회사의 2024 유도 인센티브 수상 계획에 따라 Nasdaq 상장 규칙 5635(c)(4)에 따라 이루어졌습니다.
부여의 세부 사항은 다음과 같습니다:
- 총 부여된 옵션: 5,900
- 부여 날짜: 2024년 10월 15일
- 행사 가격: 주당 $4.49(부여일의 종가)
- 부여 일정: 1년 후 25%, 나머지는 다음 3년 동안 매달 부여됨
이 주식 옵션은 Elicio Therapeutics에 합류하는 새로운 직원들을 위한 유도 수단으로 작용하며, 직원이 계속 재직하는 조건입니다.
Elicio Therapeutics (Nasdaq: ELTX), une société de biotechnologie en phase clinique axée sur le développement de nouvelles immunothérapies contre le cancer, a annoncé l'octroi d'options d'actions d'incitation à deux nouveaux employés. Les attributions, approuvées par le Comité de Compensation du Conseil d'Administration d'Elicio, ont été effectuées dans le cadre du Plan d'Attribution d'Incentives d'Induction 2024 de l'entreprise, conformément à la Règle de cotation 5635(c)(4) de Nasdaq.
Les détails des attributions sont les suivants :
- Options totales accordées : 5 900
- Date d'octroi : 15 octobre 2024
- Prix d'exercice : 4,49 $ par action (prix de clôture à la date d'octroi)
- Calendrier d'acquisition : 25 % après un an, le reste sera acquis mensuellement pendant les trois années suivantes
Ces options d'actions servent de moyen d'incitation pour les nouveaux employés rejoignant Elicio Therapeutics et sont soumises à leur maintien dans l'entreprise.
Elicio Therapeutics (Nasdaq: ELTX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung neuartiger immuntherapeutischer Ansätze gegen Krebs konzentriert, hat die Gewährung von Induktionsaktienoptionen an zwei neue Mitarbeiter angekündigt. Die Genehmigungen, die vom Vergütungsausschuss des Verwaltungsrats von Elicio genehmigt wurden, erfolgten im Rahmen des Unternehmensplans für Induktionsanreizleistungen 2024 gemäß der Nasdaq-Listing-Regel 5635(c)(4).
Die Einzelheiten der Gewährungen sind wie folgt:
- Insgesamt gewährte Optionen: 5.900
- Gewährungsdatum: 15. Oktober 2024
- Ausübungspreis: 4,49 $ pro Aktie (Schlusskurs am Gewährungsdatum)
- Vesting-Plan: 25 % nach einem Jahr, der Rest wird monatlich über die folgenden drei Jahre vested
Diese Aktienoptionen dienen als Anreiz für die neuen Mitarbeiter, die zu Elicio Therapeutics stoßen, und unterliegen ihrer fortdauernden Beschäftigung im Unternehmen.
- Elicio Therapeutics is attracting new talent to support its clinical-stage pipeline
- The company has an established incentive plan to align employee interests with shareholders
- None.
BOSTON, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio Therapeutics” or “Elicio”), a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer, today announced that on October 15, 2024, Elicio granted an aggregate of 5,900 inducement stock options to two new employees, as an inducement material to each individual entering into employment with Elicio in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement stock options were approved by the Compensation Committee of Elicio’s Board of Directors and granted under the Elicio Therapeutics, Inc. 2024 Inducement Incentive Award Plan.
Each grant provides for the purchase of shares of Elicio common stock at a price of
The grants vest over four years, with 25 percent of the shares vesting on the first anniversary of each employee’s respective start date, and the remainder vesting ratably at the end of each subsequent month thereafter, subject to such employee’s continued service relationship with Elicio through the applicable vesting dates.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing a pipeline of novel lymph node-targeted immunotherapies for the treatment of some of the most aggressive cancers. By combining expertise in immunology and immunotherapy, Elicio is harnessing the natural power of the immune system with the AMP technology, which allows for therapeutic payloads to be delivered directly to the lymph nodes, with the goal of enhancing the immune system’s cancer-fighting capabilities. By targeting cancer immunotherapies to the core of the immune response, AMP aims to optimize the lymph nodes’ natural ability to educate, activate and amplify cancer-specific T cells, which are essential for recognizing and eliminating tumor cells. Engineered to synchronize immunity in these highly potent sites, AMP is built to enhance the magnitude, potency, quality and durability of the immune response to drive antitumor activity. Elicio’s R&D pipeline includes off-the-shelf therapeutic cancer vaccines ELI-002, (targeting mKRAS-driven cancers) as well as ELI-007 and ELI-008 (targeting BRAF-driven cancers and p53 hotspot mutations, respectively). For more information, please visit www.elicio.com.
Investor Relations Contact
Robert Connelly
Elicio Therapeutics
IR@elicio.com
857-209-0153
FAQ
How many inducement stock options did Elicio Therapeutics (ELTX) grant on October 15, 2024?
What is the exercise price for the inducement stock options granted by Elicio Therapeutics (ELTX)?
What is the vesting schedule for the inducement stock options granted by Elicio Therapeutics (ELTX)?
Under which plan were the inducement stock options granted by Elicio Therapeutics (ELTX)?
